Status:
UNKNOWN
Comparison of pCR Rate After Neadjuvant Chemotherapy Guided by Result of in Vitro Cell Culture Drug Sensitivity or Physician's Choice
Lead Sponsor:
Peking University People's Hospital
Conditions:
Breast Cancer
Neoadjuvant Chemotherapy
Eligibility:
FEMALE
18-70 years
Phase:
EARLY_PHASE1
Brief Summary
Neoadjuvant chemotherapy is an important treatment for breast cancer patients. Patients with triple negative or Her2 enriched subtype who achieved pCR after neoadjuvant chemotherapy would have longer ...
Detailed Description
Neoadjuvant chemotherapy for breast cancer could make unresectable breast cancer be resectable and improve breast conservation rate. Patients with triple negative or Her2 enriched subtype who achieved...
Eligibility Criteria
Inclusion
- invasive breast cancer candidate for neoadjuvant chemotherapy normal liver and renal function agreed to participate in this experiment
Exclusion
- inflammatory breast cancer patients can not receive operation after neoadjuvant chemotherapy distant metastasis
Key Trial Info
Start Date :
December 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04130750
Start Date
December 1 2019
End Date
December 1 2021
Last Update
October 17 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People'S Hospital
Beijing, Beijing Municipality, China, 100044